For example, several RAS mutants, such as RASV12Y32F and RASV12T35S are insufficient to activate RAF in vitro, suggesting that RAF kinase activation requires other factors.13 A recent study indicates that the activation of RAF necessitates dimerization, and exploring RAF activation is currently being viewed as a potential target for therapeutic intervention in several clinical contexts, including diverse cancer types.10 The gene discussed is RAF1; the disease is cancer.